FGFR2 maintains cancer cell differentiation via AKT signaling in esophageal squamous cell carcinoma

References

• Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah M, Lagergren P, Cunningham D. Oesophageal cancer. Nat Rev Dis Prim. 2017;3. doi:10.1038/nrdp.2017.48.
   PubMedGoogle Scholar
• Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet. 2017;390(10110):2383–2396. doi:10.1016/S0140-6736(17)31462-9.
   PubMed Web of Science ®Google Scholar
• Kato K, Cho BC, Takahashi M, Okada M, Lin C, Chin K, Kadowaki S, Ahn M, Hamamoto Y, Doki Y, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506–1517. doi:10.1016/S1470-2045(19)30626-6
   PubMed Web of Science ®Google Scholar
• Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23(10):1124–1134. doi:10.1038/nm.4409.
   PubMed Web of Science ®Google Scholar
• Najafi M, Mortezaee K, Ahadi R. Cancer stem cell (a)symmetry & plasticity: tumorigenesis and therapy relevance. Life Sci. 2019;231:116520. doi:10.1016/j.lfs.2019.05.076.
   PubMed Web of Science ®Google Scholar
• Najafi M, Mortezaee K, Majidpoor J. Cancer stem cell (CSC) resistance drivers. Life Sci. 2019;234:116781. doi:10.1016/j.lfs.2019.116781.
   PubMed Web of Science ®Google Scholar
• Natsuizaka M, Kinugasa H, Kagawa S, Whelan KA, Naganuma S, Subramanian H, Chang S, Nakagawa K, Rustgi N, Kita Y, et al. IGFBP3 promotes esophageal cancer growth by suppressing oxidative stress in hypoxic tumor microenvironment. Am J Cancer Res. 2014;4(1):29–41. http://www.ncbi.nlm.nih.gov/pubmed/24482736 Accessed 2020 Jul 21.
   PubMed Web of Science ®Google Scholar
• Kinugasa H, Whelan KA, Tanaka K, Natsuizaka M, Long A, Guo A, Chang S, Kagawa S, Srinivasan S, Guha M, et al. Mitochondrial SOD2 regulates epithelial-mesenchymal transition and cell populations defined by differential CD44 expression. Oncogene. 2015;34(41):5229–5239. doi:10.1038/onc.2014.449
   PubMed Web of Science ®Google Scholar
• Kagawa S, Natsuizaka M, Whelan KA, Facompre N, Naganuma S, Ohashi S, Kinugasa H, Egloff A, Basu D, Gimotty P, et al. Cellular senescence checkpoint function determines differential Notch1-dependent oncogenic and tumor-suppressor activities. Oncogene. 2015;34(18):2347–2359. doi:10.1038/onc.2014.169
   PubMed Web of Science ®Google Scholar
• Maehara O, Suda G, Natsuizaka M, Ohnishi S, Komatsu Y, Sato F, Nakai M, Sho T, Morikawa K, Ogawa K, et al. Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma. Carcinogenesis. 2017;38(11):1073–1083. doi:10.1093/carcin/bgx095
   PubMed Web of Science ®Google Scholar
• Sato F, Kubota Y, Natsuizaka M, Maehara O, Hatanaka Y, Marukawa K, Terashita K, Suda G, Ohnishi S, Shimizu Y, et al. EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition. Cancer Biol Ther. 2015;16(6):933–940. doi:10.1080/15384047.2015.1040959
   PubMed Web of Science ®Google Scholar
• Natsuizaka M, Whelan KA, Kagawa S, Tanaka K, Giroux V, Chandramouleeswaran P, Long A, Sahu V, Darling D, Que J, et al. Interplay between Notch1 and Notch3 promotes EMT and tumor initiation in squamous cell carcinoma. Nat Commun. 2017;8(1):1–16. doi:10.1038/s41467-017-01500-9
   PubMedGoogle Scholar
• Shimokawa M, Ohta Y, Nishikori S, Matano M, Takano A, Fujii M, Date S, Sugimoto S, Kanai T, Sato T. Visualization and targeting of LGR5 + human colon cancer stem cells. Nature. 2017;545(7653):187–192. doi:10.1038/nature22081.
   PubMed Web of Science ®Google Scholar
• Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013;501(7467):328–337. doi:10.1038/nature12624.
   PubMed Web of Science ®Google Scholar
• Kijima T, Nakagawa H, Shimonosono M, Chandramouleeswaran P, Hata T, Sahu V, Kasagi Y, Kikuchi O, Tanaka K, Giroux V, et al. Three-dimensional organoids reveal therapy resistance of esophageal and oropharyngeal squamous cell carcinoma cells. Cell Mol Gastroenterol Hepatol. 2019;7(1):73–91. doi:10.1016/j.jcmgh.2018.09.003
   PubMed Web of Science ®Google Scholar
• Whelan KA, Muir AB, Nakagawa H. Esophageal 3D culture systems as modeling tools in esophageal epithelial pathobiology and personalized medicine. Cell Mol Gastroenterol Hepatol. 2018;5(4):461–478. doi:10.1016/j.jcmgh.2018.01.011.
   PubMed Web of Science ®Google Scholar
• Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10(2):116–129. doi:10.1038/nrc2780.
   PubMed Web of Science ®Google Scholar
• Holzmann K, Grunt T, Heinzle C, Sampl S, Steinhoff H, Reichmann N, Kleiter M, Hauck M, Marian B. Alternative splicing of fibroblast growth factor receptor IgIII loops in cancer. J Nucleic Acids. 2012;2012:12. doi:10.1155/2012/950508.
   Google Scholar
• Touat M, Ileana E, Postel-Vinay S, André F, Soria JC. Targeting FGFR signaling in cancer. Clin Cancer Res. 2015;21(12):2684–2694. doi:10.1158/1078-0432.CCR-14-2329.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wu C, Lu G, Hu Z, Chen Q, Du X. FGF/FGFR signaling pathway involved resistance in various cancer types. J Cancer. 2020;11(8):2000–2007. doi:10.7150/jca.40531.
   PubMed Web of Science ®Google Scholar
• Kasagi Y, Chandramouleeswaran PM, Whelan KA, Tanaka K, Giroux V, Sharma M, Wang J, Benitez A, DeMarshall M, Tobias J, et al. The esophageal organoid system reveals functional interplay between notch and cytokines in reactive epithelial changes. Cell Mol Gastroenterol Hepatol. 2018;5(3):333–352. doi:10.1016/j.jcmgh.2017.12.013
   PubMed Web of Science ®Google Scholar
• Natsuizaka M, Ohashi S, Wong GS, Ahmadi A, Kalman R, Budo D, Klein-Szanto A, Herlyn M, Diehl J, Nakagawa H. Insulin-like growth factor-binding protein-3 promotes transforming growth factor-b1-mediated epithelial-to-mesenchymal transition and motility in transformed human esophageal cells. Carcinogenesis. 2010;31(8):1344–1353. doi:10.1093/carcin/bgq108.
   PubMed Web of Science ®Google Scholar
• Prochazka L, Tesarik R, Turanek J. Regulation of alternative splicing of CD44 in cancer. Cell Signal. 2014;26(10):2234–2239. doi:10.1016/j.cellsig.2014.07.011.
   PubMed Web of Science ®Google Scholar
• Xia P, Xu XY. PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. Am J Cancer Res. 2015;5(5):1602–1609. https://pubmed.ncbi.nlm.nih.gov/26175931/.
   PubMed Web of Science ®Google Scholar
• Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med Res Rev. 2014;34(2):280–300. doi:10.1002/med.21288.
   PubMed Web of Science ®Google Scholar
• Ueno N, Shimizu A, Kanai M, Iwaya Y, Ueda S, Nakayama J, Seo M. Enhanced expression of fibroblast growth factor receptor 3 IIIc promotes human esophageal carcinoma cell proliferation. J Histochem Cytochem. 2016;64(1):7–17. doi:10.1369/0022155415616161.
   PubMed Web of Science ®Google Scholar
• Shi Y, Liu X, Fredimoses M, Song M, Chen H, Liu K, Lee M, Dong Z. FGFR2 regulation by picrasidine Q inhibits the cell growth and induces apoptosis in esophageal squamous cell carcinoma. J Cell Biochem. 2018;119(2):2231–2239. doi:10.1002/jcb.26385.
   PubMed Web of Science ®Google Scholar
• Takase N, Koma Y, Urakawa N, Nishio M, Arai N, Akiyama H, Shigeoka M, Kakeji Y, Yokozaki H. NCAM- and FGF-2-mediated FGFR1 signaling in the tumor microenvironment of esophageal cancer regulates the survival and migration of tumor-associated macrophages and cancer cells. Cancer Lett. 2016;380(1):47–58. doi:10.1016/j.canlet.2016.06.009.
   PubMed Web of Science ®Google Scholar
• Shin WS, Lee HW, Lee ST. Catalytically inactive receptor tyrosine kinase PTK7 activates FGFR1 independent of FGF. FASEB J. 2019;33(11):12960–12971. doi:10.1096/fj.201900932R.
   PubMed Web of Science ®Google Scholar
• Rivas S, Gómez-Oro C, Antón I, Wandosell F. Role of Akt isoforms controlling cancer stem cell survival, phenotype and self-renewal. Biomedicines. 2018;6(1):29. doi:10.3390/biomedicines6010029.
   PubMed Web of Science ®Google Scholar
• Almozyan S, Colak D, Mansour F, Alaiya A, Al-Harazi O, Qattan A, Al-Mohanna F, Al-Alwan M, Ghebeh H. PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation. Int J Cancer. 2017;141(7):1402–1412. doi:10.1002/ijc.30834.
   PubMed Web of Science ®Google Scholar
• Li K, Yang L, Li J, Guan C, Zhang S, Lao X, Ouyang D, Zheng G, Gao S, Wang D, et al. TGFβ induces stemness through non-canonical AKT-FOXO3a axis in oral squamous cell carcinoma. EBioMedicine. 2019;48:70–80. doi:10.1016/j.ebiom.2019.09.027.
   PubMed Web of Science ®Google Scholar
• Yang Z, Zhang C, Feng Y, Qi W, Cui Y, Xuan Y. Tenascin-C is involved in promotion of cancer stemness via the Akt/HIF1ɑ axis in esophageal squamous cell carcinoma. Exp Mol Pathol. 2019;109:104239. doi:10.1016/j.yexmp.2019.03.007.
   PubMed Web of Science ®Google Scholar
• Zhang HF, Wu C, Alshareef A, Gupta N, Zhao Q, Xu X, Jiao J, Li E, Xu L, Lai R. The PI3K/AKT/c-MYC axis promotes the acquisition of cancer stem-like features in esophageal squamous cell carcinoma. Stem Cells. 2016;34(8):2040–2051. doi:10.1002/stem.2395.
   PubMed Web of Science ®Google Scholar
• Wang W, He S, Zhang R, Peng J, Guo D, Zhang J, Xiang B, Li L. ALDH1A1 maintains the cancer stem-like cells properties of esophageal squamous cell carcinoma by activating the AKT signal pathway and interacting with β-catenin. Biomed Pharmacother. 2020;125:109940. doi:10.1016/j.biopha.2020.109940.
   PubMed Web of Science ®Google Scholar
• Liu C, Chou K, Hsu J, Lin J, Hsu T, Yen D, Hung S, Hsu H. High metabolic rate and stem cell characteristics of esophageal cancer stem-like cells depend on the Hsp27–AKT–HK2 pathway. Int J Cancer. 2019;145(8):2144–2156. doi:10.1002/ijc.32301.
   PubMed Web of Science ®Google Scholar
• Kumazoe M, Takai M, Bae J, Hiroi S, Huang Y, Takamatsu K, Won Y, Yamashita M, Hidaka S, Yamashita S, et al. FOXO3 is essential for CD44 expression in pancreatic cancer cells. Oncogene. 2017;36(19):2643–2654. doi:10.1038/onc.2016.426
   PubMed Web of Science ®Google Scholar
• Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y, Nakao S, Motoyama N, Hirao A. TGF-Β-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature. 2010;463(7281):676–680. doi:10.1038/nature08734.
   PubMed Web of Science ®Google Scholar
• Viaene AI, Baert JH. Expression of cytokeratin-mRNAs in squamous-cell carcinoma and balloon-cell formation of human oesophageal epithelium. Histochem J. 1995;27(1):69–78. doi:10.1007/BF00164174.
   PubMedGoogle Scholar
• Banks-Schlegel S, Green H. Involucrin synthesis and tissue assembly by keratinocytes in natural and cultured human epithelia. J Cell Biol. 1981;90(3):732–737. doi:10.1083/jcb.90.3.732.
   PubMed Web of Science ®Google Scholar
• Xiong Z, Ren S, Chen H, Liu Y, Huang C, Zhang Y, Odera J, Chen T, Kist R, Peters H, et al. PAX9 regulates squamous cell differentiation and carcinogenesis in the oro-oesophageal epithelium. J Pathol. 2018;244(2):164–175. doi:10.1002/path.4998
   PubMed Web of Science ®Google Scholar
• Luo A, Yu X, Li G, Ma G, Chen H, Ding F, Li Y, Liu Z. Differentiation-associated genes regulated by c-Jun and decreased in the progression of esophageal squamous cell carcinoma. PLoS One. 2014;9(5). doi:10.1371/journal.pone.0096610.
   Web of Science ®Google Scholar
• Ohashi S, Natsuizaka M, Naganuma S, Kagawa S, Kimura S, Itoh H, Kalman R, Nakagawa M, Darling D, Basu D, et al. A NOTCH3-mediated squamous cell differentiation program limits expansion of EMT-competent cells that express the ZEB transcription factors. Cancer Res. 2011;71(21):6836–6847. doi:10.1158/0008-5472.CAN-11-0846
   PubMed Web of Science ®Google Scholar
• Ohashi S, Natsuizaka M, Yashiroohtani Y, Kalman R, Nakagawa M, Wu L, Kleinszanto A, Herlyn M, Diehl J, Katz J, et al. NOTCH1 and NOTCH3 coordinate esophageal squamous differentiation through a csl-dependent transcriptional network. Gastroenterology. 2010;139(6):2113–2123. doi:10.1053/j.gastro.2010.08.040
   PubMed Web of Science ®Google Scholar
• Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990 Nov 1;76(9):1704–1709. doi:10.1182/blood.V76.9.1704.1704.
   PubMed Web of Science ®Google Scholar
• Campos B, Wan F, Farhadi M, Ernst A, Zeppernick F, Tagscherer KE, Ahmadi R, Lohr J, Dictus C, Gdynia G, et al. Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res. 2010 May 15;16(10):2715–2728. doi:10.1158/1078-0432.CCR-09-1800.
   PubMed Web of Science ®Google Scholar
• Tso JL, Yang S, Menjivar JC, Yamada K, Zhang Y, Hong I, Bui Y, Stream A, McBride WH, Liau LM, et al. Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide. Mol Cancer. 2015 Nov 6;14:189. doi:10.1186/s12943-015-0459-1.
   PubMed Web of Science ®Google Scholar
• González-Gómez P, Crecente-Campo J, Zahonero C, De La Fuente M, Hernández-Laín A, Mira H, Sánchez-Gómez P, Garcia-Fuentes M. Controlled release microspheres loaded with BMP7 suppress primary tumors from human glioblastoma. Oncotarget. 2015 May 10;6(13):10950–10963. doi:10.18632/oncotarget.3459.
   PubMedGoogle Scholar